Cardiac Dimensions, Inc. Announces Achievement of Implant Target for TITAN Safety Study

KIRKLAND, Wash.--(BUSINESS WIRE)--Cardiac Dimensions®, Inc. today announced that it achieved the implant target for the TITAN™ safety study during the fourth quarter of 2008. TITAN™ (TIghten The Annulus Now), a 30 patient study using the CARILLON™ Mitral Contour System™, is conducted at 6 centers in Germany, Poland, and France and has a primary endpoint of safety as measured by major adverse events at 30 days. The study also has secondary endpoints of long term safety and the effect of the CARILLON implant on hemodynamics and subject function at 1, 6, 12, 18, and 24 months. Follow up for all patients is now ongoing. The CARILLON Mitral Contour System, currently under investigational use in Europe, is used for percutaneous treatment of functional mitral regurgitation (FMR).